Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

2.090 +0.010 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study
Via ACCESSWIRE
Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023
Via ACCESSWIRE
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies
Via ACCESSWIRE
Ensysce Presents "A New Generation of Safer Pain Treatments"
Via ACCESSWIRE
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Investors will want to get ready for another busy day of trading as we cover the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium
Via ACCESSWIRE
Ensysce Biosciences Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Announces IRB Approval of Key Study Protocol
Via ACCESSWIRE
Ensysce Biosciences Announces Engagement of Alacrita Consulting
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Ensysce Biosciences Stock Surged Today
Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares popped Monday following positive coverage from HC Wainwright. The firm put a price target on the stock far above current levels. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Ensysce Biosciences to Participate in Upcoming Industry Events
Via ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share. 
Via Benzinga
Nasdaq Edges Lower; ISM Manufacturing PMI Drops In June
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite trading lower on Monday. The Dow traded up 0.16% to 34,462.62 while the NASDAQ fell 0.03% to 13,784.02. The S&P 500, also... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 3, 2023
 
Via Benzinga
Why Is Ensysce Biosciences (ENSC) Stock Up 50% Today?
With Ensysce Biosciences achieving testing success regarding its overdose protection drug, ENSC stock soared on the implications. 
Via InvestorPlace
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
Via ACCESSWIRE
Ensysce Biosciences Regains Compliance with Nasdaq
Via ACCESSWIRE
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 63 companies hit new 52-week lows. 
Via Benzinga
Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.